Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Income (2016 - 2020)

Syndax Pharmaceuticals has reported Net Income over the past 6 years, most recently at -$19.9 million for Q4 2020.

  • Quarterly results put Net Income at -$19.9 million for Q4 2020, down 39.81% from a year ago — trailing twelve months through Sep 2021 was -$19.9 million (up 69.8% YoY), and the annual figure for FY2025 was -$250.4 million, up 20.16%.
  • Net Income for Q4 2020 was -$19.9 million at Syndax Pharmaceuticals, roughly flat from -$19.9 million in the prior quarter.
  • Over the last five years, Net Income for SNDX hit a ceiling of -$8.4 million in Q2 2016 and a floor of -$19.9 million in Q4 2020.
  • Median Net Income over the past 5 years was -$15.1 million (2017), compared with a mean of -$15.4 million.
  • Biggest five-year swings in Net Income: tumbled 145.93% in 2016 and later increased 26.52% in 2019.
  • Syndax Pharmaceuticals' Net Income stood at -$10.9 million in 2016, then crashed by 74.99% to -$19.0 million in 2017, then dropped by 1.61% to -$19.3 million in 2018, then increased by 26.52% to -$14.2 million in 2019, then crashed by 39.81% to -$19.9 million in 2020.
  • The last three reported values for Net Income were -$19.9 million (Q4 2020), -$19.9 million (Q3 2020), and -$16.6 million (Q2 2020) per Business Quant data.